Express News | Innovent Biologics-Taletrectinib Shrank Tumors in 91% of Patients Who Were Ros1 Tki-Naïve, 52% of Patients Who Were Previously Treated With Crizotinib

ReutersJun 2 01:17 ET

Express News | Innovent Announces Taletrectinib（Ros1 Inhibitor）Updated Data From Pivotal Phase 2 Trust-I Study of Are Published in the Jco and Orally Presentedat 2024 Asco Annual Meeting

ReutersJun 2 01:15 ET

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients With Advanced Pancreatic Cancer or Biliary Tract Cancer

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerc

PR NewswireJun 1 20:00 ET

Cinda Biotech's phase III clinical study of picontibalizumab (IBI112) for the treatment of moderate to severe plaque psoriasis reached a major end point and plans to submit a marketing application

San Francisco, China, May 28, 2024/PRNewswire/ -- Cinda Biopharmaceuticals Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as tumors, autoimmunity, metabolism, cardiovascular, and ophthalmology, today announced its self-developed recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection (R&D code: IBI112) in subjects with moderate to severe plaque psoriasis in China (R&D code:) (CLEAR-1) Nakata Owner

PR NewswireMay 27 20:00 ET

[Broker Focus] CMB International: China's pharmaceutical industry is expected to return to healthy growth and continues to be optimistic about leading innovative drugs and devices and high-growth medical consumer stocks

Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has declined by 21.4%, significantly outperforming the MSCI China Index by 32.5%. The MSCI China Healthcare Index has only rebounded 9% since its low on April 19; currently, the dynamic price-earnings ratio of the industry index is 26.3 times, which is still below the 12-year historical average. It is expected that the medical equipment trade-in policy will soon be implemented. The policy is strong, wide-ranging, and has a long duration, which will effectively stimulate demand for medical devices. The bank looks forward to the introduction of a national policy to support innovative drugs and innovative devices. The bank expects that as industry-supporting policies fall one after another

金吾財訊May 27 03:30 ET

Everbright Securities: Cinda Biotetuzumab Injection Application Accepted to Maintain Purchase Rating

Everbright Securities released a research report stating that it maintains the “buy” rating of Cinda Biotech (01801), the sales performance of core products is strong, and many major products have already entered the advanced clinical stage. As a domestic star innovative pharmaceutical company, the bank is optimistic about the company's rich commercial product portfolio to provide complete comprehensive solutions for a wider and more segmented patient group. The company announced that the National Drug Administration (NMPA) Drug Evaluation Center (CDE) has officially accepted tetuumab injection (recombinant anti-insulin-like growth factor 1 receptor antibody (IGF-1R antibody), R&D code: IBI311)

新浪港股May 23 22:19 ET